Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial
Zhigang Wei,Xia Yang,Xin Ye,Qingliang Feng,Yanjun Xu,Licheng Zhang,Wenqiao Sun,Yuting Dong,Qi Meng,Tao Li,Chuntang Wang,Guangxu Li,Kaixian Zhang,Peishun Li,Jingwang Bi,Guoliang Xue,Yahong Sun,Lijun Sheng,Bin Liu,Guohua Yu,Haipeng Ren,Junye Wang,Lijun Sun,Shaoshui Chen,Dianzhong Geng,Benhua Zhang,Xin Xu,Liangming Zhang,Dengjun Sun,Xinglu Xu,Cunqi Diao,Guanghui Huang,Wenhong Li,Xiaoying Han,Jiao Wang,Min Meng,Yang Ni,Aimin Zheng,Weijun Fan,Yuliang Li,Fan Li,Hua Fan,Zhigeng Zou,Qingyu Li,Hui Tian
DOI: https://doi.org/10.1007/s00330-019-06613-x
IF: 7.034
2020-01-01
European Radiology
Abstract:Objectives This prospective trial was performed to verify whether microwave ablation (MWA) in combination with chemotherapy could provide superior survival benefit compared with chemotherapy alone. Materials and methods From March 1, 2015, to June 20, 2017, treatment-naïve patients with pathologically verified advanced or recurrent non-small cell lung cancer (NSCLC) were randomly assigned to MWA plus chemotherapy group or chemotherapy group. The primary endpoint was progression-free survival (PFS), while the secondary endpoints included overall survival (OS), time to local progression (TTLP), and objective response rate (ORR). The complications and adverse events were also reported. Results A total of 293 patients were randomly assigned into the two groups. One hundred forty-eight patients with 117 stage IV tumors were included in the MWA plus chemotherapy group. One hundred forty-five patients with 113 stage IV tumors were included in the chemotherapy group. The median follow-up period was 13.1 months and 12.4 months, respectively. Median PFS was 10.3 months (95% CI 8.0–13.0) in the MWA plus chemotherapy group and 4.9 months (95% CI 4.2–5.7) in the chemotherapy group (HR = 0.44, 95% CI 0.28–0.53; p < 0.0001). Median OS was not reached in the MWA plus chemotherapy group and 12.6 months (95% CI 10.6–14.6) in the chemotherapy group (HR = 0.38, 95% CI 0.27–0.53; p < 0.0001) using Kaplan-Meier analyses with log-rank test. The median TTLP was 24.5 months, and the ORR was 32% in both groups. The adverse event rate was not significantly different in the two groups. Conclusions In patients with advanced NSCLC, longer PFS and OS can be achieved with the treatment of combined MWA and chemotherapy than chemotherapy alone. Key Points • Patients treated with MWA plus chemotherapy had superior PFS and OS over those treated with chemotherapy alone. • The ORR of patients treated with MWA plus chemotherapy was similar to that of those treated with chemotherapy alone. • Complications associated with MWA were common but tolerable and manageable.